According to a new research report “Urinary Tract Infection (UTI) Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, UTI therapeutics currently exhibits a proliferating pipeline with 20+ therapeutic candidates.

UTI Therapeutics Pipeline Insights

UTI is an infection caused in any part of the urinary tract including urethra, ureter, bladder, and kidney. This may happen due to the invasion of bacteria causing infection, which spreads from large intestine to anus. In most cases, UTI is caused by Escherichia coli, and may affect kidneys, if left untreated. Pain and redness in belly and pelvic area are some of the common symptoms of the disease along with burning sensation while urinating. In men, the infection might occur due to the restriction of urine flow because of other diseases, including prostate enlargement.

UTI can be diagnosed through physical examination and urine tests. Apart from antibiotics, patients are advised to drink lots of fluids to flush out the infection. Two types of UTI (simple and complicated) are expected to be treated differently. For instance, the simple UTI can be cured by short duration of antibiotics and home remedies, while the complicated UTI is expected to be cured by long term antibiotics usually given intravenously for better relief.

Monurol (Zambon Switzerland Ltd.), Zemdri (Achaogen Inc.), and Avycaz (Allergan plc) are some of the drugs to cure UTIs.

Insights into Pipeline Segments

According to the research, many drugs being developed for UTI are to be administered orally. It has been found that the oral route of administration is easy to use, cost-effective, and convenient.

Positive Clinical Trial Results are Expected to Drive UTI Therapeutics Pipeline

There are several companies that are involved in developing therapeutics for UTI have shown positive results of clinical trials. For instance, in 2017, Paratek Pharmaceuticals Inc. announced positive data from safety and efficacy trials of omadacycline. The result showed that overall safety and tolerability of omadacycline in this study was consistent with prior studies. Across all studies, most frequent treatment-emergent adverse events (TEAEs) in all groups were gastrointestinal (GI), including nausea and vomiting. In general, the GI TEAEs were mild, did not result in treatment discontinuation, and were usually self-limiting.

Browse report overview with detailed TOC on "Urinary Tract Infection (UTI) Therapeutics – Pipeline Analysis 2019, Clinal Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.pharmaproff.com/report/utis-therapeutics-pipeline

Strategic Advancements Play a Pivotal Role in UTI Therapeutics Development

In the wake of strategic development, various companies are investing in development of drugs and therapies for UTIs, and also tend to expand their portfolio in the near future. For instance, in October 2016, Fimbrion Therapeutics Inc. and GlaxoSmithKline plc entered into a collaboration to develop a small molecule drug for the treatment and prevention of UTIs.

Some of the significant players for UTI therapeutics are AmpliPhi Biosciences Corporation, Achaogen Inc., Procter & Gamble, Fimbrion Therapeutics Inc., GlaxoSmithKline plc, Advancis Pharmaceutical Corporation, Paratek Pharmaceuticals Inc., Zambon Switzerland Ltd., Allergan plc, and Iterum Therapeutics Limited.

UTI Therapeutics Pipeline Analysis

• By Phase
• By Molecule Type
• By Route of Administration
• By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of UTI. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the UTI therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to UTI.